

## **Supplementary Online Content**

# **Data-Driven Subtyping of Parkinson's Disease Using Longitudinal Clinical Records: A Cohort Study**

Xi Zhang, PhD<sup>1</sup>, Jingyuan Chou, MS<sup>1</sup>, Jian Liang, PhD<sup>2</sup>, Cao Xiao, PhD<sup>3</sup>, Yize Zhao, PhD<sup>1</sup>, Harini Sarva, MD<sup>4</sup>, Claire Henchcliffe, MD, DPhil<sup>4</sup>, Fei Wang, PhD<sup>1</sup>

<sup>1</sup>Department of Healthcare Policy and Research. Weill Cornell Medical College, New York, NY, USA

<sup>2</sup>Department of Automation. Tsinghua University. Beijing. China.

<sup>3</sup>AI for Healthcare. IBM Research. Cambridge. MA. USA.

<sup>4</sup>Department of Neurology, Weill Cornell Medical College, New York, NY, USA

### **Corresponding Author:**

Fei Wang, PhD  
Department of Healthcare Policy and Research  
Weill Cornell Medicine  
425 East 61 Street, Suite 301  
New York, NY 10060  
Phone: +1 646 962 9405  
[few2001@med.cornell.edu](mailto:few2001@med.cornell.edu)

This supplementary material has been provided by the authors to give readers additional information about their work.

**Table 1: The details of target variables**

	Variable Name
<b>1</b>	Clinical Diagnosis
<b>2</b>	Demographics
<b>3</b>	Motor symptoms: MDS-UPDRS scores*
<b>4</b>	Cognitive Assessments: MoCA*
<b>5</b>	Cognitive Categorization: Normal Cognition; Mild Cognitive Impairment; Dementia
<b>6</b>	Other nonmotor variable: REM* Sleep Disorder
<b>7</b>	Biospecimen: Lumbar Puncture Sample Collection
<b>8</b>	Biospecimen: Laboratory Procedures containing DNA, RNA, Urine, Plasma, & Serum samples
<b>9</b>	Imaging Results: DaTScan Striatal Binding Ratio
<b>10</b>	Imaging Results: Magnetic Resonance Imaging

\* Abbreviations: MDS-UPDRS: Movement Disorders Society-revised Unified Parkinson's Disease Rating Scale; MoCA: Montreal Cognitive Assessment; REM: rapid eye movement

**Table 2: Comparisons of p-values obtained by clustering different representation learning methods. The significant characteristics with p-value<.05 over 6-year follow-up as well as the progression during 6 years are marked by √**

	Target Features Subtyping		All Features Subtyping		LSTM Representation Subtyping	
	6-Year Follow-up	Progression	6-Year Follow-up	Progression	6-Year Follow-up	Progression
Age onset	√		√		√	
Education			√			
H&Y Stage	√	√	√		√	√
MDS-UPDRS Part I	√	√		√	√	√
MDS-UPDRS Part II	√	√			√	√
MDS-UPDRS Part III	√		√			√
MDS-UPDRS Part IV				√		
MoCA	√	√			√	√
BJLO	√				√	√
ESS					√	
RBD	√			√	√	√
GDS	√	√		√	√	√
HVLT	√	√		√	√	√
LNS	√	√			√	√
SCOPA-AUT	√				√	
Semantic Fluency	√					√
STAI					√	
SDM	√				√	√
CSF Total tau					√	
CSF Abeta 42			√		√	
DaTScan Caudate	√	√			√	√
DaTScan Putamen	√	√			√	√
Medication Use	√	√	√	√	√	√

\*Abbreviations: MDS-UPDRS: Movement Disorders Society-revised Unified Parkinson's Disease Rating Scale; MoCA: Montreal Cognitive Assessment; BJLO: Benton Judgment of Line Orientation; ESS: Epworth Sleepiness Scale; RBD: Rapid eye movement sleep Behavior Disorder; GDS: Geriatric Depression Scale; HVLT: Hopkin's Verbal Learning Test; LNS: Letter Number Sequencing; SCOPA-AUT: SCales for Outcomes

in PArkinson's disease-AUTomatic symptoms; STAI: State Trait Anxiety Inventory; SDM: Symbol Digit Modalities; CSF: Cerebrospinal fluid; DaTScan SBR: DaTScan Striatal Binding Ratio.


**Table 3: Group Characteristics of patients at their 2nd year in the three subtypes**

	Total	Subtype I	Subtype II	Subtype III	p-value
H&Y	1.77(0.50)	1.68 (0.48)	1.54 (0.55)	1.95 (0.48)	<0.0001 <sup>a</sup> , I vs III, II vs III
MDS-UPDRS Part I	6.84 (4.53)	5.43 (3.46)	5.25 (4.88)	9.05 (4.76)	<0.0001 <sup>a</sup> , I vs III, II vs III
MDS-UPDRS Part II	7.56 (4.95)	6.03 (3.74)	4.78 (3.63)	10.23 (5.37)	<0.0001 <sup>a</sup> , I vs III, II vs III
MDS-UPDRS Part III	24.61 (10.46)	21.56 (9.48)	21.2 (8.22)	29.33 (10.39)	0.0315 <sup>a</sup> , I vs III, II vs III
MDS-UPDRS Part IV	0.93 (1.90)	0.76 (1.70)	0.17 (0.37)	1.19 (2.15)	0.8854 <sup>b</sup>
MoCA	26.14 (3.12)	27.17 (2.24)	27.33 (1.70)	24.95 (3.56)	0.4980 <sup>a</sup>
BJLO	19.18 (6.99)	20.96 (7.00)	15.88 (5.72)	17.32 (6.47)	0.0491 <sup>a</sup> , I vs II, I vs III
ESS	6.48 (3.89)	5.71 (3.52)	3.75 (2.09)	6.64 (3.82)	0.0063 <sup>a</sup> , I vs III, II vs III
RBD <sup>#</sup>	3.30 (2.94)	2.45 (2.41)	2.00 (2.35)	4.86 (3.13)	0.0035 <sup>a</sup> , I vs III, II vs III
GDS	5.64 (1.73)	5.28 (1.36)	5.33 (1.65)	6.26 (2.06)	0.0016 <sup>a</sup> , I vs III
HVLT	24.05 (5.46)	26.41 (4.07)	24.5 (4.33)	20.29 (5.42)	<0.0001 <sup>a</sup> , I vs III, II vs III
LNS	9.84 (3.53)	11.02 (2.93)	8.33 (4.19)	8.35 (3.56)	0.0050 <sup>a</sup> , I vs II, I vs III
QUIP	0.13 (0.37)	0.12 (0.36)	0.08 (0.28)	0.16 (0.40)	0.9460 <sup>a</sup>
SCOPA-AUT	12.47 (6.75)	10.17 (5.11)	8.83 (5.18)	16.67 (7.19)	0.0028 <sup>a</sup> , I vs III, II vs III
Semantic Fluency	50.09 (13.32)	53.89 (12.12)	49.58 (11.14)	44.28 (13.29)	0.3445 <sup>a</sup>
STAI	64.61 (19.16)	61.34 (16.03)	56.83 (13.65)	70.62 (22.33)	0.5784 <sup>a</sup>
SDMT	40.20 (10.85)	32.79 (11.08)	42.00 (5.46)	44.79 (8.13)	0.2780 <sup>a</sup>
Medication Use <sup>#</sup>	2.01 (1.89)	2.31 (1.93)	0.29 (0.61)	2.05 (1.83)	<0.0001 <sup>a</sup> , I vs II, II vs III


<sup>a</sup>Chi-square test; <sup>b</sup>Fisher exact test. The specific different subtypes determined by use of Tukey post hoc analysis ( $p<0.05$ ). Abbreviations: H&Y: Hoehn and Yahr; MDS-UPDRS: Movement Disorders Society-revised Unified Parkinson's Disease Rating Scale; MoCA: Montreal Cognitive Assessment; BJLO: Benton Judgment of Line Orientation; ESS: Epworth Sleepiness Scale; RBD: Rapid eye movement sleep Behavior Disorder; GDS: Geriatric Depression Scale; HVLT: Hopkin's Verbal Learning Test; LNS: Letter Number Sequencing; QUIP: Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease; SCOPA-AUT: SCales for Outcomes in PArkinson's disease-AUTomatic symptoms; STAI: State Trait Anxiety Inventory; SDMT: Symbol Digit Modalities Test; MCI: Mild Cognitive Impairment. <sup>#</sup>RBD's rating scale is 0-10; MCI was determined by patients with cognitive declines, no functional impairment, and values of cognitive tests HVLT, BJLO, LNS, Semantic Fluency and SDMT; 1=normal, 2=Abnormal, not clinically significant, 3=Abnormal, clinically significant; Medication Use defined by 0=Unmedicated for PD, 1=Levodopa, 2=Dopamine Agonist, 3=Other, 4=Levodopa & Other, 5=Levodopa & Dopamine Agonist, 6=Dopamine Agonist & Other, 7=Levodopa & Dopamine Agonist & Other.

**Table 4: Characteristics summarization of the learned subtypes**


Subtype I (43.1%)	Subtype II (22.9%)	Subtype III (33.9%)
58.79 years at baseline	61.93 years at baseline	65.32 years at baseline
Mild motor symptoms at baseline	Moderate motor symptoms at baseline	Severe motor symptoms at baseline
Mild non-motor symptoms at baseline	Moderate non-motor symptoms at baseline	Severe non-motor symptoms at baseline
Moderate motor decline	Mild motor decline	Severe motor decline
Stable cognition, moderate RBD decline	Mild non-motor decline	Severe non-motor decline
Moderate DaTScan SBR decline	Mild DaTScan SBR decline	Severe DaTScan SBR decline




**Figure 1: Comparisons of three subtypes on disease progression of the variables ESS, BJLO, GDS, and RBD.** The time interval between baseline and follow-up is 6 years. The larger slope illustrates a more rapid progression on the corresponding variables. The representative variables with the p-value<0.05 are shown.




**Figure 2: Comparisons of three subtypes on disease progression of the variables MCI and HVLT.** The time interval between baseline and follow-up is 6 years. The larger slope illustrates a more rapid progression on the corresponding variables. The representative variables with the p-value<0.05 are shown.



**Figure 3: Comparisons of three subtypes on disease progression of the variables DaTScan Caudate and Putamen.** The time interval between baseline and follow-up is 6 years. The larger slope illustrates a more rapid progression on the corresponding variables. The representative variables with the p-value<0.05 are shown.



**Figure 4: Heatmap illustration of the first-order difference of mean values for each subtype in LSTM results.** It is obtained by the difference between the mean value of baseline and the mean value of the patients' last records on the variables. The red color represents a worse progression and the blue color shows a better progression on the symptoms of PD. The darker the color is, the significant the trend is. Variables with p-value<0.05 are shown.



**Figure 5: Patient correlation of three subtypes and RBD subtypes at baseline, median time point, and 6-year follow-up.** Patients are categorized into RBD subtypes including Positive subtype, Negative subtype. The longitudinal correlation of three subtypes with Positive subtype and Negative subtype are plotted by lines respectively.

**Table 5: Multivariate logistic regression model to find discriminant clinical predictors of Subtype I patients at baseline.**

Age adjusted				Age unadjusted			
variables	coefficient	95% CI	p-value	variables	coefficient	95% CI	p-value
Age	-1.200	[-3.083, 0.635]	0.2039				
MDS-UPDRS Part I	-3.578	[-5.875, -1.406]	0.0016 <sup>#</sup>	MDS-UPDRS Part I	-3.500	[-5.801, -1.325]	0.0021 <sup>#</sup>
MDS-UPDRS Part II	0.113	[-2.015, 2.247]	0.9168	MDS-UPDRS Part II	0.165	[-1.950, 2.282]	0.8775
MDS-UPDRS Part III	-0.642	[-2.968, 1.637]	0.5823	MDS-UPDRS Part III	-0.547	[-2.871, 1.729]	0.6391
BJLO	4.327	[2.501, 6.339]	<0.0001 <sup>#</sup>	BJLO	4.319	[2.497, 6.327]	<0.0001 <sup>#</sup>
ESS	-1.592	[-3.449, 0.222]	0.0880	ESS	-1.560	[-3.410, 0.249]	0.0935
GDS	-0.526	[-2.550, 1.485]	0.6075	GDS	-0.335	[-2.315, 1.642]	0.7387
HVLT	5.057	[3.160, 7.087]	<0.0001 <sup>#</sup>	HVLT	5.202	[3.325, 7.216]	<0.0001 <sup>#</sup>
LNS	0.185	[-1.923, 2.323]	0.8639	LNS	0.463	[-1.597, 2.559]	0.6609
MoCA	-0.517	[-2.328, 1.281]	0.5725	MoCA	-0.501	[-2.310, 1.295]	0.5843
QUIP	0.028	[-1.509, 1.534]	0.9701	QUIP	0.045	[-1.485, 1.542]	0.9532
RBD	-0.969	[-2.281, 0.322]	0.1427	RBD	-0.884	[-2.187, 0.400]	0.1788
SCOPA-AUT	-1.611	[-4.055, 0.744]	0.1868	SCOPA-AUT	-2.052	[-4.407, 0.209]	0.0805
Semantic Fluency	2.227	[-0.349, 4.840]	0.0918	Semantic Fluency	2.288	[-0.267, 4.882]	0.0809
STAI	-0.528	[-2.354, 1.292]	0.5688	STAI	-0.315	[-2.091, 1.465]	0.7270
<b>SDM</b>	<b>2.536</b>	<b>[-0.247, 5.449]</b>	<b>0.0799</b>	<b>SDM</b>	<b>3.123</b>	<b>[0.479, 5.907]</b>	<b>0.0237<sup>#</sup></b>
CAUDATE.RIGHT*	-0.713	[-4.314, 2.877]	0.6963	CAUDATE.RIGHT*	-0.482	[-4.067, 3.095]	0.7911

CAUDATE.LEFT*	3.173	[-0.314, 6.734]	0.0766	CAUDATE.LEFT*	3.022	[-0.449, 6.557]	0.0897
PUTAMEN.RIGHT*	1.329	[-1.739, 4.447]	0.3982	PUTAMEN.RIGHT*	1.171	[-1.872, 4.258]	0.4527
PUTAMEN.LEFT*	-4.076	[-7.603,-0.563]	0.0222 <sup>#</sup>	PUTAMEN.LEFT*	-4.016	[-7.535, -0.501]	0.0241 <sup>#</sup>
Duration	-1.131	[-2.666, 0.387]	0.1442	Duration	-1.201	[-2.737, 0.317]	0.1210
Education	-1.590	[-3.825, 0.597]	0.1571	Education	-1.771	[-3.985, 0.390]	0.1111
H&Y	0.301	[-0.386, 1.006]	0.3947	HY	0.255	[-0.426, 0.953]	0.4661
MCI	0.049	[-0.780, 0.873]	0.9055	MCI	0.021	[-0.807, 0.844]	0.9584
Gender	-0.074	[-0.739, 0.585]	0.8240	Gender	-0.055	[-0.721, 0.605]	0.8696

\* Statistical significant correlation (p-value<0.05); \* LEFT/RIGH means left/right Caudate or Putamen; Bold variables are p-values changed from significant (not significant) to not significant (significant), with/without Age adjustment.

**Table 6: Multivariate logistic regression model to find discriminant clinical predictors of Subtype II patients at baseline.**

variables	Age adjusted			Age unadjusted			
	coefficient	95% CI	p-value	variables	coefficient	95% CI	p-value
Age	0.680	[-1.889, 3.340]	0.6075				
MDS-UPDRS Part I	3.941	[0.905, 7.050]	0.0112 <sup>#</sup>	MDS-UPDRS Part I	3.851	[0.829, 6.962]	0.0130 <sup>#</sup>
MDS-UPDRS Part II	-3.886	[-7.620,-0.613]	0.0281 <sup>#</sup>	MDS-UPDRS Part II	-3.846	[-7.589, -0.574]	0.0300 <sup>#</sup>
MDS-UPDRS Part III	-0.414	[-4.020, 3.078]	0.8181	MDS-UPDRS Part III	-0.419	[-4.018, 3.065]	0.8153
BJLO	-3.508	[-5.680,-1.413]	0.0011 <sup>#</sup>	BJLO	-3.547	[-5.721, -1.452]	0.0010 <sup>#</sup>
ESS	1.196	[-1.169, 3.552]	0.3162	ESS	1.163	[-1.198, 3.512]	0.3288
GDS	-0.093	[-2.991, 2.716]	0.9484	GDS	-0.213	[-3.080, 2.573]	0.8814
HVLT	-1.869	[-4.429, 0.623]	0.1447	HVLT	-1.964	[-4.504, -0.510]	0.1225
LNS	-1.489	[-4.413, 1.313]	0.3053	LNS	-1.673	[-4.516, 1.068]	0.2377
MoCA	1.107	[-1.120, 3.473]	0.3410	MoCA	1.175	[-1.028, 3.524]	0.3082
QUIP	1.433	[-0.756, 3.358]	0.1623	QUIP	1.441	[-0.746, 3.363]	0.1595
RBD	-1.266	[-3.456, 0.759]	0.2363	RBD	-1.303	[-3.482, 0.708]	0.2200
SCOPA-AUT	-3.826	[-7.696, -0.349]	0.0396 <sup>#</sup>	SCOPA-AUT	-3.604	[-7.407, -0.235]	0.0470 <sup>#</sup>
Semantic Fluency	0.555	[-3.000, 3.962]	0.7531	Semantic Fluency	0.527	[-3.020, 3.925]	0.7648
STAI	-4.205	[-7.213, -1.441]	0.0041 <sup>#</sup>	STAI	-4.289	[-7.278, -1.552]	0.0031 <sup>#</sup>
SDM	3.054	[-0.825, 6.934]	0.1204	SDM	2.649	[-0.900, 6.249]	0.1440
CAUDATE.RIGHT*	5.915	[1.191, 10.890]	0.0160 <sup>#</sup>	CAUDATE.RIGHT*	5.744	[1.078, 10.639]	0.0177 <sup>#</sup>
CAUDATE.LEFT*	-6.080	[-10.716,-1.639]	0.0082 <sup>#</sup>	CAUDATE.LEFT*	-6.016	[-10.629,-1.599]	0.0085 <sup>#</sup>
PUTAMEN.RIGHT*	-0.156	[-3.945, 3.500]	0.9340	PUTAMEN.RIGHT*	-0.059	[-3.811, 3.570]	0.9746
PUTAMEN.LEFT*	9.115	[5.057, 13.562]	<0.0001 <sup>#</sup>	PUTAMEN.LEFT*	9.115	[5.069, 13.547]	<0.0001 <sup>#</sup>
Duration	1.538	[-0.521, 3.500]	0.1298	Duration	1.581	[-0.460, 3.533]	0.1168
Education	1.160	[-1.704, 4.082]	0.4287	Education	1.328	[-1.479, 4.182]	0.3546
HY	-0.584	[-1.616, 0.406]	0.2542	HY	-0.541	[-1.556, 0.435]	0.2835
MCI	-0.040	[-1.555, 1.279]	0.9545	MCI	-0.019	[-1.517, 1.291]	0.9782

Gender	0.417	[-0.450, 1.320]	0.3518	Gender	0.404	[-0.463, 1.306]	0.3681
--------	-------	-----------------	--------	--------	-------	-----------------	--------

# Statistical significant correlation (p-value<0.05); \* LEFT/RIGH means left/right Caudate or Putamen.

**Table 7: Multivariate logistic regression model to find discriminant clinical predictors of Subtype III patients at baseline.**

Age adjusted				Age unadjusted			
variables	coefficient	95% CI	p-value	variables	coefficient	95% CI	p-value
Age	1.465	[-0.745,3.749]	0.1995				
MDS-UPDRS Part I	2.696	[0.349,5.109]	0.0256 <sup>#</sup>	MDS-UPDRS Part I	0.119	[0.013, 0.229]	0.0286 <sup>#</sup>
MDS-UPDRS Part II	0.752	[-1.488,3.021]	0.5101	MDS-UPDRS Part II	0.033	[-0.058,0.128]	0.4734
MDS-UPDRS Part III	1.573	[-1.002,4.261]	0.2395	MDS-UPDRS Part III	0.026	[-0.020, 0.755]	0.2745
BJLO	-2.457	[-4.448,-0.513]	0.0138 <sup>#</sup>	BJLO	-0.107	[-0.192,-0.024]	0.0118 <sup>#</sup>
ESS	1.037	[-0.948,3.078]	0.3108	ESS	0.047	[-0.051,0.149]	0.3462
GDS	0.549	[-1.788,2.905]	0.6449	GDS	0.042	[-0.188, 0.274]	0.7176
HVLT	-4.768	[-7.053,-2.624]	<0.0001 <sup>#</sup>	HVLT	-0.182	[-0.266, -0.103]	<0.0001 <sup>#</sup>
LNS	0.338	[-2.159,2.835]	0.7895	LNS	-0.001	[-0.143, 0.141]	0.9900
MoCA	-0.141	[-2.200,1.908]	0.8925	MoCA	-0.009	[-0.167, 0.147]	0.9039
QUIP	-0.510	[-2.280,1.238]	0.5668	QUIP	-0.247	[-1.127, 0.624]	0.5778
RBD	1.352	[-0.039, 2.767]	0.0580	RBD	0.111	[-0.014,0.239]	0.0828
SCOPA-AUT	3.891	[1.257,6.703]	0.0049 <sup>#</sup>	SCOPA-AUT	0.109	[0.046,0.177]	0.0011 <sup>#</sup>
SDM	-4.766	[-8.302,-1.471]	0.0060 <sup>#</sup>	SDM	-0.072	[-0.118,-0.030]	0.0013 <sup>#</sup>
Semantic Fluency	-2.726	[-5.946,0.418]	0.0921	Semantic Fluency	-0.034	[-0.073, 0.003]	0.0736
STAI	2.870	[0.773,5.053]	0.0082 <sup>#</sup>	STAI	0.026	[0.006, 0.048]	0.0144 <sup>#</sup>
CAUDATE.LEFT*	1.188	[-2.903,5.332]	0.5699	CAUDATE.LEFT*	0.397	[-0.824,1.636]	0.5249
CAUDATE.RIGHT*	-2.229	[-6.357,1.820]	0.2830	CAUDATE.RIGHT*	-0.707	[-1.860,0.425]	0.2228
PUTAMEN.LEFT*	-4.510	[-8.870,-0.240]	0.0397 <sup>#</sup>	PUTAMEN.LEFT*	-1.799	[-3.540, -0.096]	0.0396 <sup>#</sup>
PUTAMEN.RIGHT*	-3.037	[-6.876, 0.654]	0.1121	PUTAMEN.RIGHT*	-1.200	[-2.787, 0.328]	0.1292
Duration	0.575	[-1.247, 2.353]	0.5279	Duration	0.018	[-0.030, 0.067]	0.4381
Education	0.796	[-1.680,3.280]	0.5271	Education	0.049	[-0.066, 0.166]	0.4034
HY	-0.048	[-0.844,0.734]	0.9034	HY	-0.012	[-0.802, 0.766]	0.9762
MCI	-0.050	[-0.911,0.808]	0.9070	MCI	-0.032	[-0.893, 0.829]	0.9417
Gender	-0.258	[-1.013,0.491]	0.4986	Gender	-0.283	[-1.033, 0.462]	0.4568

# Statistical significant correlation (p-value<0.05); \* LEFT/RIGH means left/right Caudate or Putamen.

**Table 8: Multivariate logistic regression model to find discriminant clinical predictors of Subtype I patients at last records.**

Age adjusted				Age unadjusted			
variables	coefficient	95% CI	p-value	variables	coefficient	95% CI	p-value

Age	0.009	[-1.867, 1.904]	0.9920				
MDS-UPDRS Part I	-2.239	[-4.826, 0.255]	0.0832	MDS-UPDRS Part I	-2.239	[-4.826, 0.253]	0.0832
MDS-UPDRS Part II	-2.082	[-4.976, 0.747]	0.1521	MDS-UPDRS Part II	-2.083	[-4.968, 0.736]	0.1506
MDS-UPDRS Part III	-1.629	[-3.834, 0.495]	0.1388	MDS-UPDRS Part III	-1.629	[-3.831, 0.493]	0.1385
BJLO	2.098	[0.094, 4.187]	0.0436 <sup>#</sup>	BJLO	2.097	[0.097, 4.184]	0.0434 <sup>#</sup>
ESS	-1.426	[-3.337, 0.474]	0.1404	ESS	-1.427	[-3.330, 0.465]	0.1384
GDS	-1.971	[-4.469, 0.491]	0.1173	GDS	-1.973	[-4.448, 0.470]	0.1138
HVLT	3.900	[1.840, 6.046]	0.0002 <sup>#</sup>	HVLT	3.899	[1.841, 6.045]	0.0002 <sup>#</sup>
LNS	1.679	[-0.907, 4.385]	0.2117	LNS	1.677	[-0.885, 4.349]	0.2074
MoCA	2.745	[-0.697, 6.305]	0.1228	MoCA	2.744	[-0.696, 6.299]	0.1225
QUIP	0.475	[-1.347, 2.328]	0.6084	QUIP	0.475	[-1.346, 2.328]	0.6082
<b>RBD</b>	<b>-1.424</b>	<b>[-2.882,-0.005]</b>	<b>0.0514</b>	<b>RBD</b>	<b>-1.424</b>	<b>[-2.872,-0.016]</b>	<b>0.0496<sup>#</sup></b>
SCOPA-AUT	-0.472	[-2.936, 1.946]	0.7032	SCOPA-AUT	-0.469	[-2.862, 1.874]	0.6964
Semantic Fluency	2.857	[0.347, 5.478]	0.0284 <sup>#</sup>	Semantic Fluency	2.857	[0.349, 5.476]	0.0283 <sup>#</sup>
STAI	-1.022	[-2.926, 0.873]	0.2895	STAI	-1.023	[-2.915, 0.859]	0.2858
SDM	4.399	[0.462, 8.463]	0.0306 <sup>#</sup>	SDM	4.393	[0.630, 8.282]	0.0239 <sup>#</sup>
CAUDATE.RIGH T*	0.425	[-3.119, 3.992]	0.8138	CAUDATE.RIGH T*	0.423	[-3.099, 3.970]	0.8136
CAUDATE.LEFT*	3.417	[-0.439, 7.367]	0.0849	CAUDATE.LEFT*	3.418	[-0.436, 7.365]	0.0847
PUTAMEN.RIGH T*	-1.061	[-4.921, 2.739]	0.5864	PUTAMEN.RIGH T*	-1.059	[-4.892, 2.711]	0.5844
PUTAMEN.LEFT*	-4.386	<b>[-8.295, -0.594]</b>	0.0249 <sup>#</sup>	PUTAMEN.LEFT*	-4.387	<b>[-8.291, -0.599]</b>	0.0247 <sup>#</sup>
Duration	-0.863	[-2.548, 0.851]	0.3168	Duration	-0.863	[-2.546, 0.851]	0.3167
Education	-0.486	[-2.819, 1.877]	0.6836	Education	-0.485	[-2.811, 1.871]	0.6833
HY	0.029	[-0.585, 0.648]	0.9244	HY	0.029	[-0.583, 0.647]	0.9236
MCI	0.513	[-0.247, 1.298]	0.1907	MCI	0.514	[-0.246, 1.298]	0.1900
Gender	0.502	[-0.221, 1.239]	0.1761	Gender	0.502	[-0.221, 1.239]	0.1761
MED-USE <sup>a</sup>	2.296	[1.263, 3.393]	<0.0001 <sup>#</sup>	MED-USE	2.295	[1.272, 3.384]	<0.0001 <sup>#</sup>

<sup>#</sup> Statistical significant correlation (p-value<0.05); \* LEFT/RIGH means left/right Caudate or Putamen; Bold variables are p-values changed from significant (not significant) to not significant (significant), with/without Age adjustment; <sup>a</sup> Medication Use defined by 0=Unmedicated for PD, 1=Levodopa, 2=Dopamine Agonist, 3=Other, 4=Levodopa & Other, 5=Levodopa & Dopamine Agonist, 6=Dopamine Agonist & Other, 7=Levodopa & Dopamine Agonist & Other.

**Table 9: Multivariate logistic regression model to find discriminant clinical predictors of Subtype II patients at last records.**

Age adjusted				Age unadjusted			
variables	coefficient	95% CI	p-value	variables	coefficient	95% CI	p-value
Age	0.326	[-2.237, 2.928]	0.8031				
MDS-UPDRS Part	0.903	[-2.918, 4.618]	0.6335	MDS-UPDRS Part	0.938	[-2.871, 4.644]	0.6197

I				I			
MDS-UPDRS Part II	-2.043	[-6.874, 2.365]	0.3823	MDS-UPDRS Part II	-2.021	[-6.83, 2.374]	0.3858
MDS-UPDRS Part III	1.493	[-1.868, 4.826]	0.3766	MDS-UPDRS Part III	1.450	[-1.89, 4.745]	0.3861
BJLO	-2.333	[-4.882, 0.142]	0.0654	BJLO	-2.350	[-4.899, 0.129]	0.0638
ESS	-0.192	[-2.969, 2.502]	0.8894	ESS	-0.227	[-2.990, 2.451]	0.8689
GDS	0.469	[-3.396, 4.337]	0.8106	GDS	0.424	[-3.424, 4.268]	0.8276
HVLT	-5.245	[-9.095, -1.683]	0.0051 <sup>#</sup>	HVLT	-5.224	[-9.049, -1.676]	0.0051 <sup>#</sup>
LNS	-0.434	[-4.569, 3.605]	0.8334	LNS	-0.468	[-4.591, 3.564]	0.8203
MoCA	4.765	[-0.143, 10.113]	0.0668	MoCA	4.769	[-0.129, 10.107]	0.0661
QUIP	2.095	[-0.693, 4.571]	0.1097	QUIP	2.110	[-0.660, 4.574]	0.1052
RBD	-0.236	[-2.598, 1.996]	0.8384	RBD	-0.275	[-2.618, 1.930]	0.8105
SCOPA-AUT	-4.916	[-9.330, -0.890]	0.0212 <sup>#</sup>	SCOPA-AUT	-4.792	[-9.076, -0.879]	0.0206 <sup>#</sup>
Semantic Fluency	1.673	[-2.518, 5.807]	0.4270	Semantic Fluency	1.579	[-2.546, 5.648]	0.4462
STAI	-2.192	[-5.590, 0.739]	0.1714	STAI	-2.224	[-5.611, 0.693]	0.1634
SDM	-1.103	[-7.329, 4.919]	0.7244	SDM	-1.251	[-7.375, 4.634]	0.6832
CAUDATE.RIGH T*	4.259	[-0.962, 9.636]	0.1121	CAUDATE.RIGH T*	4.171	[-1.004, 9.488]	0.1160
CAUDATE.LEFT*	-6.522	[-12.918,-0.438]	0.0390 <sup>#</sup>	CAUDATE.LEFT*	-6.474	[-12.867, -0.397]	0.0403 <sup>#</sup>
PUTAMEN.RIGH T*	1.913	[-2.967, 6.943]	0.4459	PUTAMEN.RIGH T*	2.015	[-2.774, 6.984]	0.4147
PUTAMEN.LEFT*	9.991	[4.621, 15.938]	0.0005 <sup>#</sup>	PUTAMEN.LEFT*	9.940	[4.589, 15.874]	0.0005 <sup>#</sup>
Duration	1.805	[-0.441, 3.999]	0.1066	Duration	1.816	[-0.423, 4.004]	0.1037
Education	0.601	[-2.807, 4.019]	0.7277	Education	0.684	[-2.646, 4.041]	0.6862
HY	-0.838	[-1.827, 0.110]	0.0869	HY	-0.838	[-1.828, 0.111]	0.0871
MCI	-0.735	[-2.140, 0.504]	0.2686	MCI	-0.719	[-2.117, 0.512]	0.2760
Gender	-0.026	[-1.100, 1.062]	0.9614	Gender	-0.038	[-1.108, 1.046]	0.9436
MED-USE <sup>a</sup>	-4.609	[-6.939, -2.677]	<0.0001 <sup>#</sup>	MED-USE	-4.646	[-6.959, -2.725]	<0.0001 <sup>#</sup>


<sup>#</sup> Statistical significant correlation (p-value<0.05); \* LEFT/RIGH means left/right Caudate or Putamen; <sup>a</sup> Medication Use defined by 0=Unmedicated for PD, 1=Levodopa, 2=Dopamine Agonist, 3=Other, 4=Levodopa & Other, 5=Levodopa & Dopamine Agonist, 6=Dopamine Agonist & Other, 7=Levodopa & Dopamine Agonist & Other.

**Table 10: Multivariate logistic regression model to find discriminant clinical predictors of Subtype III patients at last records.**

Age adjusted				Age unadjusted			
variables	coefficient	95% CI	p-value	variables	coefficient	95% CI	p-value
Age	2.246	[-0.146, 4.746]	0.0703				
MDS-UPDRS Part I	1.795	[-0.998, 4.662]	0.2113	MDS-UPDRS Part I	1.725	[-1.100, 4.620]	0.2353
MDS-UPDRS Part II	3.421	[0.253, 6.762]	0.0381 <sup>#</sup>	MDS-UPDRS Part II	3.223	[0.084, 6.512]	0.0480 <sup>#</sup>

MDS-UPDRS Part III	1.477	[-0.907, 3.964]	0.2318	MDS-UPDRS Part III	1.492	[-0.912, 4.001]	0.2309
BJLO	-0.368	[-2.642, 1.966]	0.7531	BJLO	-0.463	[-2.727, 1.866]	0.6915
ESS	2.299	[0.006, 4.649]	0.0508	ESS	2.000	[-0.243, 4.283]	0.0814
GDS	0.922	[-1.969, 3.861]	0.5342	GDS	0.756	[-2.086, 3.621]	0.6025
HVLT	-2.821	[-5.332, -0.394]	0.0244 <sup>#</sup>	HVLT	-3.032	[-5.521, -0.635]	0.0144 <sup>#</sup>
LNS	-1.828	[-5.051, 1.263]	0.2540	LNS	-2.165	[-5.353, 0.897]	0.1724
MoCA	-4.826	[-8.710, -1.162]	0.0117 <sup>#</sup>	MoCA	-4.540	[-8.363, -0.915]	0.0163 <sup>#</sup>
QUIP	-1.524	[-3.734, 0.632]	0.1673	QUIP	-1.462	[-3.655, 0.678]	0.1809
RBD	1.576	[0.023, 3.187]	0.0496 <sup>#</sup>	RBD	1.338	[-0.184, 2.906]	0.0882
SCOPA-AUT	3.637	[0.637, 6.827]	0.0205 <sup>#</sup>	SCOPA-AUT	4.119	[1.219, 7.229]	0.0069 <sup>#</sup>
SF	-5.021	[-8.295, -1.944]	0.0018 <sup>#</sup>	SF	-4.956	[-8.173, -1.931]	0.0017 <sup>#</sup>
STAI	2.529	[0.384, 4.740]	0.0219 <sup>#</sup>	STAI	2.179	[0.077, 4.344]	0.0437 <sup>#</sup>
SDM	-3.197	[-7.855, 1.345]	0.1714	SDM	-4.251	[-8.765, 0.134]	0.0600
CAUDATE.RIGH T*	-0.081	[-3.974, 3.788]	0.9668	CAUDATE.RIGHT*	-0.256	[-4.087, 3.561]	0.8947
CAUDATE.LEFT*	0.086	[-4.458, 4.651]	0.9700	CAUDATE.LEFT*	-0.059	[-4.565, 4.462]	0.9795
<b>PUTAMEN.RIGH T*</b>	<b>-5.313</b>	<b>[-10.397, -0.51]</b>	<b>0.0343<sup>#</sup></b>	<b>PUTAMEN.RIGHT*</b>	<b>-4.776</b>	<b>[-9.784, -0.048]</b>	<b>0.0535</b>
PUTAMEN.LEFT*	-2.657	[-8.128, 2.700]	0.3355	PUTAMEN.LEFT*	-2.659	<b>[-8.096, 2.629]</b>	0.3294
Duration	0.194	[-1.914, 2.253]	0.8544	Duration	0.136	[-1.976, 2.197]	0.8978 <sup>B</sup>
Education	-0.947	[-4.014, 2.024]	0.5372	Education	-0.621	[-3.637, 2.299]	0.6808
HY	0.261	[-0.492, 1.021]	0.4955	HY	0.352	[-0.392, 1.105]	0.3542
MCI	-0.038	[-0.881, 0.794]	0.9285	MCI	-0.017	[-0.860, 0.814]	0.9673
Gender	-0.945	[-1.821, -0.103]	0.0302 <sup>#</sup>	Gender	-0.849	[-1.708, -0.020]	0.0474 <sup>#</sup>
MED-USE <sup>a</sup>	0.286	[-0.956, 1.552]	0.6527	MED-USE <sup>a</sup>	-0.007	[-1.202, 1.195]	0.9907

<sup>#</sup> Statistical significant correlation (p-value<0.05); \* LEFT/RIGH means left/right Caudate or Putamen; Bold variables are p-values changed from significant (not significant) to not significant (significant), with/without Age adjustment; <sup>a</sup> Medication Use defined by 0=Unmedicated for PD, 1=Levodopa, 2=Dopamine Agonist, 3=Other, 4=Levodopa & Other, 5=Levodopa & Dopamine Agonist, 6=Dopamine Agonist & Other, 7=Levodopa & Dopamine Agonist & Other.



**Figure 6: The LSTM recurrent neural network.** (A) the simple recurrent neural network architecture. (B) long short-term memory cell.

Figure 4 shows the architecture of LSTM. The input vector at time step  $t$  of the  $p$ th patient can be denoted as  $x_t \in R^d, t = 1, \dots, N_p$ , where the number of unique record timestamps for the patient is  $N_p$  and  $d$  is the dimensionality input feature. The number of total records provided for the model is an aggregation of patient records  $N = \sum_p N_p$ . Each patient may have a different length of record sequences. We subsequently introduce a memory cell, which is employed in hidden layer  $h_t$  at timestamp  $t$ . We used a simplified version of the memory unit in Figure 4B. Mathematically, it is implemented by the following composite functions:

$$\begin{aligned} i_t &= \sigma(W_i x_t + W_i h_{t-1} + b_i) \\ f_t &= \sigma(W_f x_t + W_f h_{t-1} + b_f) \\ o_t &= \sigma(W_o x_t + W_o h_{t-1} + b_o) \\ c_t &= f_t \cdot c_{t-1} + i_t \cdot \tanh(W_c x_t + W_c h_{t-1} + b_c) \\ h_t &= o_t \cdot \tanh(c_t) \end{aligned}$$

where  $\sigma(x) = 1/(1 + \exp(-x))$  is the logistic sigmoid function,  $i$ ,  $f$ ,  $o$  and  $c$  are the input gate, forget gate, output gate, and cell state, respectively. The vector  $h_t \in R^k, k \ll d$  is a compact continuous low-dimensional embedding for each input  $x_t$ . There are two types of target features: binary and continuous. We construct two different types of losses to measure the prediction performance at each time stamp. Specifically, for each timestamp  $t$ , the loss on binary dimension  $y_t^b$  is measured by the following penalized logistic loss:

$$\sum_t \sum_{j=1}^{m_b} \log(1 + \exp(-y_{t,j}^b (w_{b,j}^T h_t))) + \lambda \|W_b\|_F^2$$

where  $j$  indicates the dimension of binary target value. For continuous targets,  $y_t^g$ , the loss is measured by the following penalized square loss:

$$\frac{1}{2} \sum_t \|y_t^g - W_g h_t\|_2^2 + \lambda \|W_g\|_F^2$$

where  $y_t^g$  is the continuous part of  $y_t$ .  $\|\cdot\|_F$  is Frobenius norm. In both loss functions,  $\lambda$  is a hyperparameter to control the contribution of regularizers. The target  $y_t \in R^m$  consists of the binary part  $y_t^b$  and continuous part  $y_t^g$ . In total, the parameter collection  $\{W_i, b_i, W_f, b_f, W_o, b_o, W_c, b_c, W_g, W_b\}$  can be optimized jointly through back-propagation and mini-batch stochastic gradient descent. We implemented the algorithm using MATLAB software.